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ABSTRACT Background: Endothelin (ET) is an endothelium-derived
multifunctional peptide that produces a potent, long-lasting vasoconstric-
tion. Nitric oxide (NO), besides being the most important endothelium-
derived relaxant factor in blood vessels, is supposed to be involved in
regulating the interactions among endothelium, adhesive molecules, and
leukocytes.
Methods:We investigated the possible occurrence and distribution of ET
and constitutive nitric oxide synthase (NOs), the enzyme that generates
NO from L-arginine, in bovine lymphatic vessels and primary culture of
lymphatic endothelium by using immunocytochemistry.
Results:Specific immunostainingwith bothET and endothelial constitu-
tive NOs antisera was detectable at light and electron microscopic levels
in the endothelial cell layer of lymphatic vessels, whereas no immunostain-
ing could be observed in themuscular and adventitial layers. The immuno-
reaction showed a diffuse pattern throughout the cytoplasm of endothe-
lial cells. Primary cultures of endothelial cells isolated from lymphatic
vessels also displayed cytoplasmic ET- and NOs-like immunoreactivities.
The endothelial nature of cell monolayers was confirmed by the positive
reaction to the von Willebrand factor, a reliable marker of endothelial
cells, and by ultrastructural features of cultured cells.
Conclusions: These findings suggest that the endothelium is a major
source of ET and NO in lymphatic vessels. Interestingly, the lymphatic
endothelium maintains the capability of producing such vasoactive sus-
tances also in vitro, thus suggesting that lymphatic endothelial cells in
culture may be used in studies concerning the role of the endothelium in
the generation of vasoactive molecules. According to previous functional
studies, the occurrence of ET and NOs immunoreactivities in lymphatic
vessel endothelium supports the view that lymphatic endothelium may
play an important role in the regulation of lymphatic vascular tone and in
the production of vascular contractile activity promoting lymph flow.
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Blood vascular endothelium releases vasoactive me-
diators that originally were called endothelium-derived
relaxing factors (EDRF) and endothelium-derived con-
tracting factors (EDCF) according to their action on the
muscular wall. Subsequent studies have provided con-
vincing evidence that endothelin (ET) and nitric oxide
(NO) are responsible for most of the contracting activity
and relaxing activity, respectively, by the regulation of
vascular smooth muscle cells via paracrine mechanism
(Palmer et al., 1987; Yanagisawa et al., 1988; Vane et
al., 1990; Moncada et al., 1991; Masaki et al., 1992;
Moncada, 1992; Moncada and Higgs, 1993).
ET is a 21-amino-acid peptide that, besides being the
most potent and long-acting vasoconstrictive peptide so
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far discovered, is able to exert several biological ac-
tions, including neuromodulation, stimulation of cell
growth, and modulation of hormone release (Yanag-
isawa et al., 1988; Rubanyi and Parker Botelho, 1991;
Masaki et al., 1992). NO is a free radical gas produced
intracellularly through the conversion of L-arginine to
L-citrulline by the enzymeNO synthase (NOs). There is
now evidence for multiple forms of this enzyme, all of
which requireNicotinamideAdenineDinucleotide Phos-
phate Reduced (NADPH) as a cofactor (Moncada et al.,
1991; Forstermann et al., 1991). One group of enzymes
is constitutive and requires calcium and calmodulin as
cofactors. The other group is inducible in response to
cytokines or endotoxin and is calcium/calmodulin inde-
pendent. Both constitutive and inducible isoforms occur
in vascular endothelium (Moncada et al., 1991;
Moncada, 1992). Under basal conditions, NO is sup-
posed to be the most important regulator of vascular
tone, and it is essential for maintaining normal vascu-
lar resistance (Ignarro et al., 1987; Palmer et al., 1987;
Moncada and Higgs, 1993). Indeed, the inactivation of
NOs causes vasoconstriction and long-lasting pressor
response (Moncada et al., 1991; Berdeaux, 1993). In-
creasing evidence now exists that NO may exert other
biological actions such as inhibition of platelet aggrega-
tion, attenuation of leukocytes and endothelium interac-
tion, and maintenance of the vascular permeability
barrier (Ignarro, 1989; Kubes and Granger, 1992).
Lymph propulsion and return from the tissues are
carried out by both passive and active driving mecha-
nisms. The passive mechanism is caused by compres-
sion and suction of lymphatic vessels, resulting from
extrinsic activities of the surrounding tissue. The pas-
sive driving system is probably the main mechanism of
propulsion of the lymph in the initial lymphatics and in
those collecting vessels with a thin smooth muscle
layer. The active driving mechanism is due to intrinsic
contractility of lymphatic vessels, promoted by the
activity of the smoothmuscle cells of the lymphatic wall
(Ohhashi et al., 1980; Drake et al., 1985; Ohhashi,
1993). The existence of the active mechanism promot-
ing the lymph flow induces the belief that local media-
tors couldmodulate smoothmuscle cell tone and contrac-
tility in lymphatic vessels. Previous investigations have
suggested that some vasoactive substances may modu-
late the contractility of the lymphatic vessel wall
(Dabney et al., 1988, 1991; Fortes et al., 1989; Dobbins
et al., 1991; Dobbins and Dabney, 1991; Ferguson and
DeFilippi, 1994). Other studies have demonstrated that
lymphatic endothelial cells are able to release vasodila-
tor agents. These findings suggested the hypothesis
that lymphatic vessels may regulate their own vascular
tone (Ohhashi and Takahashi, 1991; Bohlen and Lash,
1992; Ohhashi and Yokoyama, 1994).
Although ET-like immunoreactivity has been demon-
strated in the lymphatic vessel wall, some discrepan-
cies exist as to whether ET is localized only in the
endothelial layer or also in the muscular layer (Oh-
kuma, 1991).
In the present study, we investigated the presence of
ET and constituive NOs in lymphatic vessels and in
cultured endothelial cells by immunocytochemical reac-
tions.
MATERIALS AND METHODS
Collection of Lymphatic Vessels and Culture
of Lymphatic Endothelial Cells
Lymphatic vessels (n 5 18) were obtained from 10
bovine mesenteries from 2–3-year-old animals. The
lymphatic vessel network was delineated by injecting a
solution of 0.1% Evan’s blue in phosphate buffered
saline (PBS) into mesenteric lymph nodes. Some ves-
sels (n 5 10) were cut into small pieces and immedi-
ately fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.3, at room temperature for 3 hr. The
specimens were washed in 0.05 M Tris buffer, pH 7.4,
containing 0.1 M NaCl (0.15 M Tris buffered saline;
TBS) and 15% sucrose overnight, embedded in Tissue
Tek II OCT (Miles, Naperville, IL), rapidly frozen in
isopentane cooled by liquid nitrogen, and cut in a
cryostat.
Endothelial cells for cultures were obtained by colla-
genase digestion from other isolated lymphatic vessels
(n 5 8). Dye-filled vessels were cannulated at both ends
and washed with normal saline solution and incubated
at 37°C for 10 min. The vessels were then drained with
culture medium TC 199 containing Earle’s salts and
L-glutamine and supplemented with 20% fetal calf
serum, NaHCO3 2.2 mg/ml, penicillin 200 U/ml, and
streptomycin 200 mg/ml. After washing, the vessels
were incubated with 0.2% collagenase in saline solution
at 37°C for 5 min. The fluid was collected and placed in
Costar well plates containing coverslips for cell cul-
tures. Cells were grown at 37°C in a humidified incuba-
tor with air and 5% CO2. The cells were fixed for 5 min
in 4% paraformaldehyde in 0.1 M phosphate buffer and
washed in TBS before immunostaining.
Light Microscopy Immunocytochemistry
Sections of lymphatic vessels (at least 5/vessel; N 5
50) and primary cultures (n 5 8) of lymphatic vessel
cells were trated for the immunocytochemical reaction
to detect ET and endothelial constitutive NOs by
indirect immunofluorescence and immunoperoxidase
(Polak and Van Noorden, 1986). The demonstraction of
the endothelial nature of cultured cells was also per-
formed by the immunolocalization of the von Wille-
brand factor (vWf).
All the samples were treated with 0.3% Triton X 100
in TBS for 1 min and rinsed in TBS thoroughly.
Samples for immunoperoxidase reaction were also incu-
bated with 0.3% hydrogen peroxide in TBS for 30min to
remove endogenous peroxidase activity. Normal goat
serum, diluted to 1:20 in TBS, was applied for 30 min at
room temperature to reduce possible background stain-
ing. The samples were then incubated overnight at 4°C
with rabbit polyclonal antisera to ET, NOs, and von
Willebrand protein (dilutions between 1:50 and 1:1,000).
The samples were washed in TBS, incubated with
either tetramethylrhodamine isothiocyanate (TRITC),
conjugated or biotinylated goat anti-rabbit IgG, diluted
to 1:100 in TBS for 30 min, and then washed in TBS.
The samples were stained with TRITC antibodies
and mounted with TBS glycerol (1:1). The samples
labeled with biotinylated antibodies were incubated
with streptavidin-biotinylated peroxidase complexes
diluted to 1:200 in TBS for 1 hr at room temperature.
The samples were washed in TBS, and peroxidase was
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visualized by incubation with 0.03% 3,38-diaminobenzi-
dine tetrahydrochloride (DAB) solution in 0.05 M Tris-
HCl, pH 7.4, to which 0.02% hydrogen peroxide was
added before use.
Some sections and cell monolayers were lighly coun-
terstained with haematoxylin and mounted in DPX for
light microscope examinations.
Conventional Electron Microscopy and Electron
Microscopy Immunocytochemistry
Cultures (n 5 8) of lymphatic vessel cells were
routinely processed for electron microscopy to assess
the endothelial nature of cultured cells. Briefly, cell
culture monolayers were fixed with 2.5% glutaralde-
hyde in 0.1 M sodium cacodylate buffer, pH 7.4, for 30
min at 37°C and for 30 min at 4°C. The monolayers
were postfixed in 1% OsO4 in 0.2 M collidine buffer, pH
7.4, for 1 hr at 4°C, dehydrated, and embedded in epoxy
resin. Ultrathin sections (80 nm) were cut perpendicu-
larly to the monolayer plane and countrasted with
uranyl acetate and lead citrate for transmission elec-
tron microscope observations.
Small pieces of lymph vessels (n5 8) were fixed in 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.3, at
room temperature for 6 hr.After washing in 0.05 M Tris
buffer, pH 7.4, containing 0.1 M NaCl (TBS), the
samples were processed for the immunocytochemical
identification of ET and NOs immunoreactivities by
using a preembedding immunoperoxidase technique,
as described previously (Sexton et al., 1995). The
samples were processed according to the protocol de-
scribed for the localization of ET and NOs immunoreac-
tivities at light microscopy. After peroxidase visualiza-
tion with the DAB solution, the samples of lymphatic
vessels were fixed in 2.5% glutaraldehyde, postfixed in
1% OsO4, and routinely embedded in epoxy resin.
Immunostained lymphatic vessels were cut transver-
sally to obtain semithin and ultrathin sections. At least
three sections per lymphatic vessel were observed.
Antisera and Specificity Controls
of the Immunocytochemical Reactions
The antisera against synthetic ET-1 and endothelial
constitutive NOs were raised in rabbits and have been
characterized elsewhere (Yoshizawa et al., 1990; Casasco
et al., 1991, 1993; Springall et al., 1991, 1992; Buttery
et al., 1994). Pertinent specificity tests were performed,
including adsorption of the specific antisera with re-
lated and unrelated antigens, omission of the first
layer, and substitution of an inappropriate antiserum
or a nonimmune serum for the specific primary antisera
(Polak and Van Noorden, 1986).
As for ET antiserum, immunostaining was prevented
by adsorption of antiserumwith synthetic ET-1, -2, or -3
(10 nmol in 1 ml antiserum diluted 1:700 in TBS),
indicating that the antiserum cross reacts with differ-
ent ET isoforms.
NOs antiserum was raised against a synthetic 15-
residue peptide, based on deduced amino acid se-
quences of cDNA encoding the bovine and human
endothelial constitutive NOs (Lamas et al., 1992;
Marsden et al., 1992). The peptide sequence was
VTSRIRTQSFSLQER-C, corresponding to amino acids
1172–1186 of the deduced amino acid sequence, with a
cysteine residue at the C terminus to assist coupling to
carrier. This sequence represents a one that is identical
between the bovine and human endothelial NOs (Lamas
et al., 1992; Marsden et al., 1992) and has low homology
with other isoforms of NOs (,50% with rat brain NOs
and virtually no homology with macrophage NOs). The
peptide was coupled to maleimide-activated key-hole
limpet hemocyanin and used to immunize rabbits.
The antiserum to human von Willebrand protein
and the secondary antibodies were purchased from
Dakopatts (Glostrup, Denmark). Biotinylated probes
were purchased from Amersham International (Amer-
sham, England).
RESULTS
Immunocytochemistry
ET and NOs immunoreactivities were detectable
within endothelial cells of the isolated lymphatic ves-
sels at both light and electron microscopic levels (Figs.
1a & 1b and 2a & 2b). The immunostaining was
continuous along the endothelial layer. We saw no
specific immunostaining in the muscular or adventitial
layers with ET or NOs antisera in any of the sections
examined.
In addition, lymphatic vessel endothelial cells in
culture were immunoreactive with ET and NOs anti-
sera (Fig. 3a & 3b). The immunostaining, although
diffuse throughout the cytoplasm, appeared more in-
tense in the perinuclear portion of the cytoplasm.
Cultured cells were also positive for the demonstraction
of vWf. The reaction showed a granular pattern within
the cytoplasm (not shown).
In control samples that were not incubated with
primary antisera, no immunostaining could be ob-
served (Fig. 3c).
Electron Microscopy
At the ultrastructural level, lymphatic endothelial
cells exibited a flattened shape with a subtle profile
(Fig. 4a). The cells were joined to one another by
overlappings or interdigitations of the cellular edges.
The cytoplasm, particularly in the perinuclear regions
(Fig. 4b), contained rough endoplasmic reticulum cister-
nae, ribosomes, mitochondria, filaments, vacuoles, and
vesicles. Moreover, it usually presented Weibel-Palade
bodies, the cytoplasmic organelles characteristic of
endothelial cells.
DISCUSSION
The present study demonstrates the occurrence and
distribution of ET and constitutiveNOs immunoreactivi-
ties in the endothelium of lymphatic vessels. Because
ET and NOs immunoreactivities were observed in
lymphatic endothelium both in vivo and in vitro, we
propose that cultured lymphatic endothelial cells may
be profitably employed in further studies to investigate
the role of lymphatic endothelium in the generation of
vasoactive molecules.
To date, the exact localization of ET in lymphatic
vessel walls has not been completely satisfactory
(Okhuma, 1991). Our data confirm the occurrence of ET
in the lymphatic vascular wall and provide evidence
that this peptide is produced exclusively by the endothe-
lial cell layer. Lymphatic endothelial cells maintain
their positivity to ET reaction when removed from the
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vascular wall and cultured, as it has been demon-
strated for blood vessel endothelium (Nakamura et al.,
1990; Loesch et al., 1991). Our data are at variance with
those reported by Ohkuma (1991) who also found ET
immunoreactivity in the muscular layer of lymphatic
and blood vessels. Indeed, ET immunoreactivity has
been revealed by using immunocytochemistry in differ-
ent cell types (e.g., neurons, epithelial cells, macro-
phages), and the possible production of ET by smooth
muscle cells in vitro has been reported (Resink et al.,
1990). However, according to previous morphological
studies, we never found ET immunoreactivity or mRNA
in smooth muscle cells of any organ in vivo (MacCum-
ber et al., 1989; Casasco et al., 1991, 1993; Giaid et al.,
1991a,b; Springall et al., 1991).
Previous physiological studies have shown that lym-
phatic vessels constrict in response to exogenous ET,
thus suggesting that this peptide may contribute to the
control of lymph flow by affecting lymphatic vessels
contractility (Dobbins and Dabney, 1991). The occur-
rence of ET immunoreactivity within lymphatic endo-
thelial cells supports the view that lymphatic vessels
may modulate with a self-mechanism for their own
contractility, thus promoting the active driving mecha-
nism for lymph flow (Ohhashi, 1993).
The detection of constitutive NOs immunoreactivity
in lymphatic vessel endothelial cells in situ and in
cultured endothelial cells isolated from lymphatic ves-
sels strongly suggests that these cells are able to
produce NO. Previous studies have suggested that this
molecule might play a pivotal role in the molecular
mechanisms that regulate lymphatic vessel tone and
lymph flow (Ohhashi and Takahashi, 1991; Ohhashi
and Yokoyama, 1994). The antiserum used in our
experiments to reveal NOs was raised against the
endothelial constitutive isoform of the enzyme. Indeed,
we found specific immunostaining only within lym-
phatic endothelial cells, whereas the muscular and
adventitial layers were negative to the reaction. Never-
theless, the inducible form of NOs has been localized in
smooth muscle cells (for a review, see Moncada, 1992).
Therefore, the possibility that smooth muscle cells of
the lymphatic vessels are also able to produce the
inducible isoform of NOs cannot be excluded.
A relationship between NO synthesis and changes in
vascular permeability has been observed in blood ves-
sels (Kubes and Granger, 1992). It has been also
observed that the inactivation of NO by superoxide may
be an important event at the onset of inflammation
when leukocyte extravasation occurs (Ohhashi and
Fig. 1. Immunohistochemical localization of (a) endothelin (ET) and (b) endothelial constitutive nitric
oxide synthase (NOs) immunoreactivities in isolated bovine lymphatic vessels. The immunostaining is
confined to the endothelial layer. Immunoperoxidase method. 3800.
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Yokoyama, 1994). Moreover, a correlation in vivo be-
tween decreased NO synthesis and expression of P-
selectin, an adhesive molecule mediating the adhesion
of platelets and neuthrophyls to blood endothelium, has
been described (Davenpeck et al., 1994). Because P-
selectin has been shown to occur in lymphatic endothe-
lium (Marchetti et al., 1995; Di Nucci et al., 1996), it
may be tentatively hypothesized that NO production by
Fig. 2. Electron microscopical localization of (a) endothelin (ET) and
(b) endothelial constitutive nitric oxide synthase (NOs) immunoreac-
tivities in isolated bovine lymphatic vessels. The electron-dense
reaction product is detectable throughout the cytoplasm of endothelial
cells. The nuclei of the endothelial cells and the cells underlying the
endothelium appear negative. Immunoperoxidase method. 39,750.
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endothelial NOs may also influence P-selectin activity
in lymphatic vessels. This aspect might be important in
the mechanisms that regulate the leukocyte adhesion
to endothelial cells and extravasation.
Taken together, our immunocytochemical findings
suggest the existence in lymphatic endothelial cells of
both vasoconstrictor and vasodilator factors, namely
ET and NO, respectively, that may be involved in the
Fig. 3. Immunocytochemical localization of (a) endothelin (ET) and
(b) endothelial constitutive nitric oxide synthase (NOs) immunoreac-
tivities in cultured cells from lymphatic endothelium. Strong immuno-
staining is detectable within the cytoplasm of cultured cells. c: In
cultures used as a control of the immunoreaction (CON), no specific
staining is visible. Immunoperoxidase method. 3500.
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regulation of contractile activity of the vessel. Through
these and probably other factors, the lymphatic vessels
have the possibility to not only control the vascular tone
but also produce and regulate the contractile activity
necessary to promote the lymph flow according to the
active driving mechanism. In line with this view, mus-
cular tone has been shown to play an important role in
the regulation of spontaneous contractions in lym-
phatic vessels (Ferguson and DeFilippi, 1994; Ohhashi
and Yokoyama, 1994). However, because significant
differences exist among the vessels of different organs
with regard to the thickness of the muscular layer of
the vascular wall, it is reasonable to presume that
different vessels may have different capacities to re-
spond to vasoactive factors.
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